1. Cancer Treatment Combination of Paclitaxel, Rapamycin and 17-AAG

    The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a composition of the synergistic anticancer agents rapamycin, paclitaxel and 17-AAG, encapsulated and solubilized by nontoxic, nanoscale PEG-b-PLA micelles.

1 Item

To Top